NCT04754100

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Completed Phase 1 Last updated 6 June 2023

What this trial tests

Phase 1 trial testing agenT-797 in Relapsed/Refractory Multiple Myeloma in 13 participants. Completed in 31 May 2023.

Timeline

29 March 2021

Primary endpoint
13 January 2023

31 May 2023

Quick facts

Lead sponsor	MiNK Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	29 March 2021
Primary completion	13 January 2023
Estimated completion	31 May 2023
Sites	3 locations across United States

Drugs / interventions tested

• agenT-797 — full drug profile →

Conditions studied

• Relapsed/Refractory Multiple Myeloma — all drugs for Relapsed/Refractory Multiple Myeloma →

Sponsor

MiNK Therapeutics — full company profile →

Who can join

18 and older, any sex, with Relapsed/Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
   Daver NG, Maiti A, Kadia TM, Vyas P, et al · · 2022 · cited 126× · PMID 36218325 · DOI 10.1158/2159-8290.cd-22-0332
2. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.
   Courtney AN, Tian G, Metelitsa LS. · · 2023 · cited 59× · PMID 36347021 · DOI 10.1182/blood.2022016201
3. Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes.
   Look A, Burns D, Tews I, Roghanian A, et al · · 2023 · cited 31× · PMID 37153585 · DOI 10.3389/fimmu.2023.1176724
4. Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.
   Delfanti G, Dellabona P, Casorati G, Fedeli M. · · 2022 · cited 29× · PMID 35615083 · DOI 10.3389/fmed.2022.897750
5. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.
   Hammond TC, Purbhoo MA, Kadel S, Ritz J, et al · · 2024 · cited 25× · PMID 38321023 · DOI 10.1038/s41467-024-44905-z
6. Targeting Natural Killer T Cells in Solid Malignancies.
   Ingram Z, Madan S, Merchant J, Carter Z, et al · · 2021 · cited 24× · PMID 34072042 · DOI 10.3390/cells10061329
7. Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.
   Reina-Ortiz C, Giraldos D, Azaceta G, Palomera L, et al · · 2022 · cited 13× · PMID 35159200 · DOI 10.3390/cells11030392
8. Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.
   Singer M, Valerin J, Zhang Z, Zhang Z, et al · · 2025 · cited 6× · PMID 39936958 · DOI 10.3390/cells14030166